ADIPONECTIN AS A POTENTIAL BIOMARKER OF LOW BONE MINERAL DENSITY IN POSTMENOPAUSAL WOMEN WITH METABOLIC SYNDROME

Overview

Journal Acta Endocrinol (Buchar)

Specialty Endocrinology

Date 2019 Jun 1

PMID 31149258

Citations 8

Authors

S S Stojanovic

N A Arsenijevic

A Djukic

S Djukic

S Zivancevic Simonovic

M Jovanovic

N Pejnovic

V Nikolic

S Zivanovic

M Stefanovic

D Petrovic

Affiliations

Soon will be listed here.

Abstract

Context: Adiponectin is an abundant adipokine, which has antiinflammatory, anti-atherosclerotic and vasoprotective actions, and potential antiresorptive effects on bone metabolism. It seems to be directly involved in the improvement and control of energy homeostasis, protecting bone health and predicting osteoporotic fracture risk.

Objective: To examine the relationship between adiponectin level and bone mineral density (BMD) in post-menopausal women with metabolic syndrome (MetS) and low BMD, and to estimate the prognostic significance of adiponectin in osteoporosis.

Design: Clinical-laboratory cross-sectional study including 120 middle-aged and elder women (average 69.18±7.56 years).

Subjects And Methods: The anthropometric parameters were measured for all examinees. Lumbar spine and hip BMD, as well as body fat percentage, were measured using a Hologic DEXA scanner. In all subjects serum adiponectin concentration was measured by ELISA method.

Results: The level of adiponectin was significantly positively correlated with BMD-total, BMD of the lumbar spine and BMD of the femoral neck (r=0.618, r=0.521, r=0.567; p<0.01). Levels of adiponectin and BMD are significantly lower in post-menopausal women with MetS and osteoporosis compared to patients with osteopenia (856.87±453.43 . 1287.32±405.21 pg/mL, p<0.01; BMD, p<0.05), and the highest values in healthy examinees. A cut-off value of adiponectin level for osteoporosis/osteopenia was 1076.22/1392.74 pg/mL.

Conclusions: Post-menopausal women with MetS have significantly lower adiponectin level and low BMD compared to healthy examinees. Adiponectin may be an early, significant and independent predictor of developing osteoporosis in women with MetS, especially in post-menopausal period.

Citing Articles

The multiple actions of dipeptidyl peptidase 4 (DPP-4) and its pharmacological inhibition on bone metabolism: a review.

Pechmann L, Pinheiro F, Andrade V, Moreira C Diabetol Metab Syndr. 2024; 16(1):175.

PMID: 39054499 PMC: 11270814. DOI: 10.1186/s13098-024-01412-x.

Interaction between Selected Adipokines and Musculoskeletal and Cardiovascular Systems: A Review of Current Knowledge.

Sierawska O, Sawczuk M Int J Mol Sci. 2023; 24(24).

PMID: 38139115 PMC: 10743430. DOI: 10.3390/ijms242417287.

Novel Adipokines and Their Role in Bone Metabolism: A Narrative Review.

Deepika F, Bathina S, Armamento-Villareal R Biomedicines. 2023; 11(2).

PMID: 36831180 PMC: 9953715. DOI: 10.3390/biomedicines11020644.

Bone mass and microarchitecture in T2DM patients and corticosteroids therapy: the Bushehr Elderly Health program.

Gharibzadeh S, Goodarzi G, Tehrani S, Fahimfar N, Razi F, Sanjari M J Diabetes Metab Disord. 2022; 21(1):717-725.

PMID: 35673425 PMC: 9167314. DOI: 10.1007/s40200-022-01040-0.

Leptin to adiponectin ratio in puberty is associated with bone mineral density in 18-year-old males.

Tamme R, Jurimae J, Maestu E, Remmel L, Purge P, Mengel E Bone Rep. 2022; 16:101158.

PMID: 34977280 PMC: 8683673. DOI: 10.1016/j.bonr.2021.101158.

References

Kajimura D, Lee H, Riley K, Arteaga-Solis E, Ferron M, Zhou B . Adiponectin regulates bone mass via opposite central and peripheral mechanisms through FoxO1. Cell Metab. 2013; 17(6):901-915. PMC: 3679303. DOI: 10.1016/j.cmet.2013.04.009. View

. Prevention and management of osteoporosis. World Health Organ Tech Rep Ser. 2004; 921:1-164, back cover. View

Zhang Y, Zhou P, Kimondo J . Adiponectin and osteocalcin: relation to insulin sensitivity. Biochem Cell Biol. 2012; 90(5):613-20. DOI: 10.1139/o2012-022. View

Richards J, Valdes A, Burling K, Perks U, Spector T . Serum adiponectin and bone mineral density in women. J Clin Endocrinol Metab. 2007; 92(4):1517-23. DOI: 10.1210/jc.2006-2097. View

DeBoer M, Gurka M, Morrison J, Woo J . Inter-relationships between the severity of metabolic syndrome, insulin and adiponectin and their relationship to future type 2 diabetes and cardiovascular disease. Int J Obes (Lond). 2016; 40(9):1353-9. PMC: 5310821. DOI: 10.1038/ijo.2016.81. View

Ozkurt B, Ozkurt Z, Altay M, Aktekin C, Caglayan O, Tabak Y . The relationship between serum adiponectin level and anthropometry, bone mass, osteoporotic fracture risk in postmenopausal women. Eklem Hastalik Cerrahisi. 2009; 20(2):78-84. View

Tenta R, Kontogianni M, Yiannakouris N . Association between circulating levels of adiponectin and indices of bone mass and bone metabolism in middle-aged post-menopausal women. J Endocrinol Invest. 2011; 35(3):306-11. DOI: 10.3275/7744. View

Tu Q, Zhang J, Dong L, Saunders E, Luo E, Tang J . Adiponectin inhibits osteoclastogenesis and bone resorption via APPL1-mediated suppression of Akt1. J Biol Chem. 2011; 286(14):12542-53. PMC: 3069456. DOI: 10.1074/jbc.M110.152405. View

Yamaguchi N, Kukita T, Li Y, Kamio N, Fukumoto S, Nonaka K . Adiponectin inhibits induction of TNF-alpha/RANKL-stimulated NFATc1 via the AMPK signaling. FEBS Lett. 2008; 582(3):451-6. DOI: 10.1016/j.febslet.2007.12.037. View

10.

Wang Z, Scherer P . Adiponectin, the past two decades. J Mol Cell Biol. 2016; 8(2):93-100. PMC: 4816148. DOI: 10.1093/jmcb/mjw011. View

11.

Qin L, Yang Z, Zhang W, Gu H, Li X, Zhu L . Metabolic syndrome and osteoporotic fracture: a population-based study in China. BMC Endocr Disord. 2016; 16(1):27. PMC: 4882795. DOI: 10.1186/s12902-016-0106-x. View

12.

Sowers M, Zheng H, Tomey K, Karvonen-Gutierrez C, Jannausch M, Li X . Changes in body composition in women over six years at midlife: ovarian and chronological aging. J Clin Endocrinol Metab. 2006; 92(3):895-901. PMC: 2714766. DOI: 10.1210/jc.2006-1393. View

13.

Berner H, Lyngstadaas S, Spahr A, Monjo M, Thommesen L, Drevon C . Adiponectin and its receptors are expressed in bone-forming cells. Bone. 2004; 35(4):842-9. DOI: 10.1016/j.bone.2004.06.008. View

14.

Liu W, Zhu X, Wang Q, Wang L . Hyperglycemia induces endoplasmic reticulum stress-dependent CHOP expression in osteoblasts. Exp Ther Med. 2013; 5(5):1289-1292. PMC: 3671778. DOI: 10.3892/etm.2013.978. View

15.

Luo Y, Liu M . Adiponectin: a versatile player of innate immunity. J Mol Cell Biol. 2016; 8(2):120-8. PMC: 4816149. DOI: 10.1093/jmcb/mjw012. View

16.

Alberti K, Zimmet P, Shaw J . Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006; 23(5):469-80. DOI: 10.1111/j.1464-5491.2006.01858.x. View

17.

Wong S, Chin K, Suhaimi F, Ahmad F, Ima-Nirwana S . The Relationship between Metabolic Syndrome and Osteoporosis: A Review. Nutrients. 2016; 8(6). PMC: 4924188. DOI: 10.3390/nu8060347. View

18.

Luo X, Guo L, Yuan L, Xie H, Zhou H, Wu X . Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway. Exp Cell Res. 2005; 309(1):99-109. DOI: 10.1016/j.yexcr.2005.05.021. View

19.

Zhang H, Xie H, Zhao Q, Xie G, Wu X, Liao E . Relationships between serum adiponectin, apelin, leptin, resistin, visfatin levels and bone mineral density, and bone biochemical markers in post-menopausal Chinese women. J Endocrinol Invest. 2010; 33(10):707-11. DOI: 10.1007/BF03346674. View

20.

Iacobellis G, Iorio M, Napoli N, Cotesta D, Zinnamosca L, Marinelli C . Relation of adiponectin, visfatin and bone mineral density in patients with metabolic syndrome. J Endocrinol Invest. 2010; 34(1):e12-5. DOI: 10.1007/BF03346703. View